|
|
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
|
1R21CA180097-01
|
$165,300
|
$165,300
|
Dittmer, Dirk
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
|
2R44CA132257-03
|
$638,567
|
$638,567
|
MORGAN, Lee
|
DEKK-TEC, INC.
|
|
|
A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of NSCLC
|
5R01CA157409-02
|
$608,827
|
$608,827
|
HOLLEN, PATRICIA
|
UNIVERSITY OF VIRGINIA
|
|
|
A Multidisciplinary and Translational Approach to Hepatobiliary Malignancy
|
5K24CA139570-04
|
$186,940
|
$186,940
|
Nelson, David
|
UNIVERSITY OF FLORIDA
|
|
|
A New Web 2.0 Platform for Analyzing Genomics Data with Application to the S
|
5R42CA139639-04
|
$490,789
|
$490,789
|
Johnson, Wayne
|
MYATT AND JOHNSON, INC.
|
|
|
A Novel Brachytherapy Agent for GBM
|
1R41CA165626-01A1
|
$299,937
|
$299,937
|
Calzone, Frank
|
APPLIED INTEGRIN SCIENCES, INC.
|
|
|
A novel diagnostic test for Irinotecan and Topotecan sensitivity
|
5R41CA162548-02
|
$240,309
|
$240,309
|
GJERSET, RUTH
|
RG BIOPHARMA, LLC
|
|
|
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
|
3R41CA174031-01S1
|
$147,010
|
$73,505
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
A Suite of Tumor Targeting Peptides for Personalized Therapy of Lung Cancer
|
5R01CA164447-02
|
$310,130
|
$310,130
|
BROWN, KATHLYNN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
A Translational Model of Evolution of Myeloma Adhesion-Mediated Drug Resistance
|
5R21CA164322-02
|
$170,730
|
$170,730
|
Silva, Ariosto
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
5R01CA168900-02
|
$312,080
|
$156,040
|
Powell, Daniel
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
|
1R01CA169519-01A1
|
$312,246
|
$312,246
|
SALVEMINI, DANIELA
|
SAINT LOUIS UNIVERSITY
|
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
7K08CA160660-03
|
$156,330
|
$78,165
|
Kentsis, Alex
|
SLOAN-KETTERING INST CAN RES
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-37S2
|
$12,499
|
$1,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-37
|
$7,216,850
|
$577,348
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
ACOSOG Community Clinical Oncology Program (CCOP) Research Base
|
5U10CA149950-03
|
$1,055,550
|
$42,222
|
Sloan, Jeff
|
MAYO CLINIC ROCHESTER
|
|
|
ACOSOG Competing Renewal
|
5U10CA076001-17
|
$2,940,780
|
$235,262
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Action of RB Pathway in Breast Cancer Therapy
|
3R01CA129134-04S1
|
$53,182
|
$53,182
|
KNUDSEN, ERIK
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Action of RB Pathway in Breast Cancer Therapy
|
7R01CA129134-04
|
$300,826
|
$300,826
|
KNUDSEN, ERIK
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Activating Bax as a therapeutic strategy for lung cancer
|
1R01CA175003-01
|
$309,952
|
$309,952
|
Li, Chi
|
UNIVERSITY OF LOUISVILLE RES FDN
|
|
|
Acupuncture to Prevent Chemotherapy Dose Reduction
|
1R21CA173263-01
|
$164,430
|
$164,430
|
Bao, Ting
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
|
Adaptable Polymer Micelles for Tumor Targeting
|
5R01CA129287-04
|
$281,401
|
$281,401
|
PARK, KINAM
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
|
|
Adoption and Retooling of GEM model for Pancreatic Cancer
|
ZIA BC 011463
|
$48,590
|
$34,013
|
Van Dyke, Terry
|
CCR (NCI)
|
|
|
Adult Brain Tumor Consortium (ABTC)
|
5U01CA137443-05
|
$1,698,364
|
$1,698,364
|
GROSSMAN, STUART
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Advancing Clinical Trails in Coastal North Carolina
|
1U10CA176852-01
|
$532,663
|
$197,085
|
MAGUIRE, PATRICK
|
NEW HANOVER REGIONAL MEDICAL CENTER
|
|
|
Aerobic Training During or After Adjuvant Therapy: A Randomized Trial
|
5R01CA164751-02
|
$231,630
|
$115,815
|
JONES, LEE
|
DUKE UNIVERSITY
|
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
7R01CA139032-05
|
$296,649
|
$296,649
|
Muschen, Markus
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
3U01CA121947-07S1
|
$5,600,000
|
$5,600,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
5U01CA121947-07
|
$6,477,537
|
$6,477,537
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
ALL therapy and developing brains: MRI measures, genetic factors and cognition
|
5R01CA090246-08
|
$357,411
|
$357,411
|
REDDICK, WILBURN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
American College of Radiology Imaging Network
|
3U10CA080098-14S2
|
$5,146,722
|
$4,014,443
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Analog Studies of 4-HPR and its Glucuronide
|
5R01CA049837-19
|
$311,800
|
$311,800
|
CURLEY, ROBERT
|
OHIO STATE UNIVERSITY
|
|
|
Analysis of Anti-Cancer Chemicals and Pharmaceutical Formulations
|
N02CM120027-002
|
$51,996
|
$51,996
|
HINES, JOHN
|
RESEARCH TRIANGLE INSTITUTE
|
|
|
Analysis of Anti-Cancer Chemiclas & Pharmaceutical Formulations
|
N02CM120026-006
|
$77,202
|
$77,202
|
WHITE, JONATHAN
|
MRIGLOBAL
|
|
|
Analysis of Redox Modulated Signaling Networks in Response to Ionizing Radiation
|
5R01CA136810-05
|
$277,303
|
$138,652
|
Furdui, Cristina
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
|
Analysis of the leukemic stem cell niche in chronic myeloid leukemia
|
5K08CA138916-04
|
$162,568
|
$162,568
|
Krause, Daniela
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
Angiocidin, a Novel Differentiation Agent for the Treatment of Leukemia
|
1R43CA173947-01A1
|
$288,301
|
$288,301
|
SWINDELL, CHARLES
|
DIFFREGEN, LLC
|
|
|
Angiogenesis-targeting therapy for glioblastoma
|
2R01CA129371-06
|
$594,234
|
$297,117
|
Batchelor, Tracy
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
|
1R21CA178344-01
|
$189,963
|
$189,963
|
ARMENIAN, SARO
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Anti-PV1 Therapy for Pancreatic Cancer
|
1R21CA172983-01A1
|
$211,410
|
$211,410
|
STAN, RADU
|
DARTMOUTH COLLEGE
|
|
|
Anti-topoisomerase drug action in yeast
|
5R01CA052814-20
|
$266,200
|
$266,200
|
NITISS, JOHN
|
UNIVERSITY OF ILLINOIS
|
|
|
Anti-Tumor Mechanisms and Therapeutic Effects of Vitamin D
|
5R01CA067267-19
|
$410,953
|
$410,953
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
Antibody directed delivery of short interfering RNA for the treatment of ovarian
|
5K08CA163603-02
|
$170,631
|
$170,631
|
PALANCA-WESSELS, MARIA
|
FRED HUTCHINSON CAN RES CTR
|
|
|
Antibody-interferon fusion proteins for treatment of B-cell malignancies
|
5R01CA162964-03
|
$300,377
|
$150,189
|
MORRISON, SHERIE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIA
|
5R01CA098787-09
|
$246,402
|
$246,402
|
NAGLE, DALE
|
UNIVERSITY OF MISSISSIPPI
|
|
|
Anticancer Drug Pharmacology in Very Young Children
|
5R01CA154619-02
|
$407,467
|
$407,467
|
STEWART, CLINTON
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
Anticancer drug-induced BH3-only protein.Bak interactions
|
5R01CA166741-02
|
$302,812
|
$302,812
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
|
|
Antifolate activators of AMP-dependent protein kinase
|
5R01CA140416-04
|
$272,639
|
$272,639
|
MORAN, RICHARD
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
|
Antitumor-Antibiotics from Marine Microorganisms
|
5R37CA044848-27
|
$350,629
|
$350,629
|
FENICAL, WILLIAM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
Apoptosome Regulation in Leukemia by Protein Phosphatase 5 Hypoacetylation
|
1F31CA174243-01
|
$32,168
|
$32,168
|
FOSS, KRISTEN
|
DUKE UNIVERSITY
|
|
Total relevant funding to Chemotherapy for this search: $466,489,513
|
